Bangalore based application research and formulation company, Bionova announced that the company is betting on the rapid development of Indian bio-pharma industry and foresee 300 per cent revenue growth by end of financial year 2017. The company is planning to launch a range of OTC products (Over-the-counter non-prescription) for infant nutrition, child growth, diabetic supplements and wellness. The new range of product line will enable Bionova to develop a competitive stand along the line of present Indian and global players in the market.  

Commenting on the announcement, Suddhir Jain, managing director, Bionova said, "We are poised to achieve a strong set of numbers during current financial year. The new organisation structure will enable us to deliver superior results while our current product range has been performing strongly. Our human wellness focused unique formulations vertical is growing at a rapid pace and will be launching an exciting range of product line over next few months. We are accelerating research and invention initiatives to establish the company as globally respected premium pharmaceutical brand, while company is remained focused on developing its pipeline products across its business segments to sustain our long term growth”.

Increasing awareness on alternative wellness products, growing confidence in OTC products, and change of prescription drugs to OTC products will drive the pharmaceutical market. The various segments of OTC products such as vitamins & minerals, gastrointestinal, and cough cold & allergy are the major reasons for the popularity of the OTC product market. Growing number of self-treatment patient base and their confidence in the OTC drugs is helping the Indian market to grow. Bionova has invested towards formulation and research activities across it OTC product range to acquire market pie in the branded formulations space.